Key points from article :
Genflow Biosciences is on a mission to develop gene therapies designed to slow the aging process.
Developing therapies that deliver a variant of the sirtuin 6 (SIRT6) gene found in centenarians.
It has a pipeline of compounds for human indications, idiopathic pulmonary fibrosis (IPF) and Werner’s syndrome.
veteran Leire says "It’s a fantastic tool but, it boxes companies into a senescence company, a mitochondria company, or a stem cell company".
SIRT6 is one of many genes that repair our DNA, from a therapeutic perspective.
It’s more interesting than others because DNA repair seems to be its only function.
SIRT6 can be easily delivered into cells, so it’s possible to use it as a gene therapy target.
Gene therapy was costlier before but today there are companies developing clinical trials with AAVs.
Leire says "Yes, we will have a trial in Werner’s syndrome, but we consider that a door opener to having a true aging indication".
Genflow’s preclinical work to continue over the next 12–18 months.
